4 years ago

Transine Therapeutics Raises £9.1 Million for Therapeutic RNA Development

  • Transine Therapeutics, a Cambridge, UK-based biotechnology company developing therapeutic RNAs, has secured £9.1 million in funding led by Takeda Ventures, Inc

  • and the Dementia Discovery Fund (DDF)

  • The funding will be used to advance the company's proprietary platform and build a pipeline of mRNA-targeted therapeutics, initially focusing on the Central Nervous System and Ophthalmology applications

  • Transine's platform utilizes SINEUPs, a novel class of naturally occurring long non-coding RNAs, to provide a unique treatment approach for challenging diseases.

      • ProblemHealthcare

      "Current treatment options for diseases like Alzheimer's and other neurological disorders are limited and often ineffective. This leaves millions of patients with few therapeutic choices and a poor prognosis."

      Solution

      "Transine Therapeutics' proprietary SINEUP® platform technology unlocks a new class of therapeutic RNAs that can target specific proteins. This allows them to develop novel treatments for hard-to-treat diseases, initially focusing on the Central Nervous System and Ophthalmology, by offering a unique mechanism of action that surpasses the limitations of traditional therapies like small molecules, biologics, and gene therapies."

      Covered on